Bio

Issac has spent over 15 years in investment banking and corporate advisory in New York and London focused primarily on the healthcare and TMT sectors. He also has experience executing cross-border transactions in emerging markets. He has worked with private equity and corporate clients on a variety of transactions and projects involving M&A, debt, equity, licensing, valuations and fundraising. In Europe, he was with the healthcare investment banking team at Bank of America, M&A team at Standard Chartered Bank, and most recently with PharmaVentures, a specialist healthcare corporate advisory firm. Prior to being in Europe, he was based in New York with JP Morgan’s M&A Telecom, Media and Technology team, and in the Healthcare and Technology teams at Salomon Smith Barney (Citigroup). A selection of Issac’s transaction experience includes advising Ossur hf on the $132 million acquisition of Gibaud SA, Management Buyout of Endo Pharmaceuticals from Du Pont Merck Pharmaceuticals, Sale of Mediq for $526 million to Bruckman Rosser Sherrill, NanoSight on the sale to Spectris plc, Inventages on the sale of Vital Foods to Mundipharma, Aura Capital on the sale of CM Technologies to Yokogawa Electric, IDT Australia on the divestment of CMAX Clinical Trial Services business to I’Rom Group, arranging £8.0 bn financing for KKR’s acquisition of Alliance Boots, arranging $1.0 bn Eurobond financing for AstraZeneca, Sinochem Resources on the $878 million acquisition of Emerald Energy, Cheung Kong Infrastructure on the £212 million acquisition of Seabank Power, initial public offering of Sonus Networks, and fairness opinion for Telecom Italia’s $800 million acquisition of Entel SA. Issac received a BA in Economics from Columbia College, a Master’s in International Affairs from Columbia University and an MBA from Columbia Business School.